<?xml version='1.0' encoding='utf-8'?>
<document id="15980690"><sentence text="Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study."><entity charOffset="10-19" id="DDI-PubMed.15980690.s1.e0" text="efavirenz" /><entity charOffset="47-58" id="DDI-PubMed.15980690.s1.e1" text="simvastatin" /><entity charOffset="60-72" id="DDI-PubMed.15980690.s1.e2" text="atorvastatin" /><entity charOffset="78-89" id="DDI-PubMed.15980690.s1.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e0" e2="DDI-PubMed.15980690.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e0" e2="DDI-PubMed.15980690.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e0" e2="DDI-PubMed.15980690.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e0" e2="DDI-PubMed.15980690.s1.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e1" e2="DDI-PubMed.15980690.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e1" e2="DDI-PubMed.15980690.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e1" e2="DDI-PubMed.15980690.s1.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e2" e2="DDI-PubMed.15980690.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s1.e2" e2="DDI-PubMed.15980690.s1.e3" /></sentence><sentence text="Efavirenz (EFV) is associated with hyperlipidemia when used in combination with other antiretroviral drugs"><entity charOffset="0-9" id="DDI-PubMed.15980690.s2.e0" text="Efavirenz" /><entity charOffset="11-14" id="DDI-PubMed.15980690.s2.e1" text="EFV" /><pair ddi="false" e1="DDI-PubMed.15980690.s2.e0" e2="DDI-PubMed.15980690.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s2.e0" e2="DDI-PubMed.15980690.s2.e1" /></sentence><sentence text=" EFV is a mixed inducer/inhibitor of cytochrome P450 (CYP) 3A4 isozyme and may interact with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4"><entity charOffset="1-3" id="DDI-PubMed.15980690.s3.e0" text="EFV" /></sentence><sentence text=" To assess the drug-drug interaction of EFV used in combination with simvastatin (SIM), atorvastatin (ATR), or pravastatin (PRA), an open-label trial was conducted in 52 healthy adult HIV-seronegative subjects across AIDS Clinical Trials Group sites in the United States"><entity charOffset="69-80" id="DDI-PubMed.15980690.s4.e0" text="simvastatin" /><entity charOffset="82-85" id="DDI-PubMed.15980690.s4.e1" text="SIM" /><entity charOffset="88-100" id="DDI-PubMed.15980690.s4.e2" text="atorvastatin" /><entity charOffset="102-105" id="DDI-PubMed.15980690.s4.e3" text="ATR" /><entity charOffset="111-122" id="DDI-PubMed.15980690.s4.e4" text="pravastatin" /><entity charOffset="124-127" id="DDI-PubMed.15980690.s4.e5" text="PRA" /><entity charOffset="40-42" id="DDI-PubMed.15980690.s4.e6" text="EFV" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e6" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e6" e2="DDI-PubMed.15980690.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e0" e2="DDI-PubMed.15980690.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e0" e2="DDI-PubMed.15980690.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e0" e2="DDI-PubMed.15980690.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e0" e2="DDI-PubMed.15980690.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e0" e2="DDI-PubMed.15980690.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e0" e2="DDI-PubMed.15980690.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e1" e2="DDI-PubMed.15980690.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e1" e2="DDI-PubMed.15980690.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e1" e2="DDI-PubMed.15980690.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e1" e2="DDI-PubMed.15980690.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e1" e2="DDI-PubMed.15980690.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e2" e2="DDI-PubMed.15980690.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e2" e2="DDI-PubMed.15980690.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e2" e2="DDI-PubMed.15980690.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e2" e2="DDI-PubMed.15980690.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e3" e2="DDI-PubMed.15980690.s4.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e3" e2="DDI-PubMed.15980690.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e3" e2="DDI-PubMed.15980690.s4.e5" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e4" e2="DDI-PubMed.15980690.s4.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s4.e4" e2="DDI-PubMed.15980690.s4.e5" /></sentence><sentence text=" Subjects received 40 mg of SIM, 10 mg of ATR, or 40 mg of PRA daily on days 0 through 3 and days 15 through 18"><entity charOffset="28-30" id="DDI-PubMed.15980690.s5.e0" text="SIM" /><entity charOffset="42-44" id="DDI-PubMed.15980690.s5.e1" text="ATR" /><entity charOffset="59-61" id="DDI-PubMed.15980690.s5.e2" text="PRA" /><pair ddi="false" e1="DDI-PubMed.15980690.s5.e0" e2="DDI-PubMed.15980690.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s5.e0" e2="DDI-PubMed.15980690.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s5.e0" e2="DDI-PubMed.15980690.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s5.e1" e2="DDI-PubMed.15980690.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s5.e1" e2="DDI-PubMed.15980690.s5.e2" /></sentence><sentence text=" EFV was administered daily at a dose of 600 mg on days 4 through 18"><entity charOffset="1-3" id="DDI-PubMed.15980690.s6.e0" text="EFV" /></sentence><sentence text=" SIM, ATR, and PRA concentrations were determined before and after EFV, and EFV concentrations were determined before and after statins"><entity charOffset="67-69" id="DDI-PubMed.15980690.s7.e0" text="EFV" /><entity charOffset="76-78" id="DDI-PubMed.15980690.s7.e1" text="EFV" /><entity charOffset="1-3" id="DDI-PubMed.15980690.s7.e2" text="SIM" /><entity charOffset="6-8" id="DDI-PubMed.15980690.s7.e3" text="ATR" /><entity charOffset="15-17" id="DDI-PubMed.15980690.s7.e4" text="PRA" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e2" e2="DDI-PubMed.15980690.s7.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e2" e2="DDI-PubMed.15980690.s7.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e2" e2="DDI-PubMed.15980690.s7.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e2" e2="DDI-PubMed.15980690.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e2" e2="DDI-PubMed.15980690.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e3" e2="DDI-PubMed.15980690.s7.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e3" e2="DDI-PubMed.15980690.s7.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e3" e2="DDI-PubMed.15980690.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e3" e2="DDI-PubMed.15980690.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e4" e2="DDI-PubMed.15980690.s7.e4" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e4" e2="DDI-PubMed.15980690.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e4" e2="DDI-PubMed.15980690.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e0" e2="DDI-PubMed.15980690.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s7.e0" e2="DDI-PubMed.15980690.s7.e1" /></sentence><sentence text=" EFV reduced SIM acid exposure (area under the curve at 0 to 24 hours [AUC0-24 h]) by 58% (Wilcoxon signed rank test, P=0"><entity charOffset="13-21" id="DDI-PubMed.15980690.s8.e0" text="SIM acid" /><entity charOffset="1-8" id="DDI-PubMed.15980690.s8.e1" text="EFV" /><pair ddi="false" e1="DDI-PubMed.15980690.s8.e1" e2="DDI-PubMed.15980690.s8.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s8.e1" e2="DDI-PubMed.15980690.s8.e0" /></sentence><sentence text="003) and active HMG-CoA reductase inhibitory activity by 60% (P&lt;0" /><sentence text="001)" /><sentence text=" EFV reduced ATR exposure by 43% (P&lt;0"><entity charOffset="1-3" id="DDI-PubMed.15980690.s11.e0" text="EFV" /><entity charOffset="13-15" id="DDI-PubMed.15980690.s11.e1" text="ATR" /><pair ddi="false" e1="DDI-PubMed.15980690.s11.e0" e2="DDI-PubMed.15980690.s11.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s11.e0" e2="DDI-PubMed.15980690.s11.e1" /></sentence><sentence text="001) and the total active ATR exposure by 34% (P=0"><entity charOffset="26-28" id="DDI-PubMed.15980690.s12.e0" text="ATR" /></sentence><sentence text="005)" /><sentence text=" EFV administration resulted in a 40% decrease in PRA exposure (P=0"><entity charOffset="1-3" id="DDI-PubMed.15980690.s14.e0" text="EFV" /><entity charOffset="50-52" id="DDI-PubMed.15980690.s14.e1" text="PRA" /><pair ddi="false" e1="DDI-PubMed.15980690.s14.e0" e2="DDI-PubMed.15980690.s14.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s14.e0" e2="DDI-PubMed.15980690.s14.e1" /></sentence><sentence text="005)" /><sentence text=" SIM, ATR, and PRA had no effect on non-steady-state EFV concentrations"><entity charOffset="53-55" id="DDI-PubMed.15980690.s16.e0" text="EFV" /><entity charOffset="1-3" id="DDI-PubMed.15980690.s16.e1" text="SIM" /><entity charOffset="6-8" id="DDI-PubMed.15980690.s16.e2" text="ATR" /><entity charOffset="15-17" id="DDI-PubMed.15980690.s16.e3" text="PRA" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e1" e2="DDI-PubMed.15980690.s16.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e1" e2="DDI-PubMed.15980690.s16.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e1" e2="DDI-PubMed.15980690.s16.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e1" e2="DDI-PubMed.15980690.s16.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e2" e2="DDI-PubMed.15980690.s16.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e2" e2="DDI-PubMed.15980690.s16.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e2" e2="DDI-PubMed.15980690.s16.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e3" e2="DDI-PubMed.15980690.s16.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s16.e3" e2="DDI-PubMed.15980690.s16.e0" /></sentence><sentence text=" In conclusion, EFV, when administered with SIM, ATR, or PRA, can result in significant induction of statin metabolism"><entity charOffset="16-18" id="DDI-PubMed.15980690.s17.e0" text="EFV" /><entity charOffset="44-46" id="DDI-PubMed.15980690.s17.e1" text="SIM" /><entity charOffset="49-51" id="DDI-PubMed.15980690.s17.e2" text="ATR" /><entity charOffset="57-59" id="DDI-PubMed.15980690.s17.e3" text="PRA" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e0" e2="DDI-PubMed.15980690.s17.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e0" e2="DDI-PubMed.15980690.s17.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e0" e2="DDI-PubMed.15980690.s17.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e0" e2="DDI-PubMed.15980690.s17.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e1" e2="DDI-PubMed.15980690.s17.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e1" e2="DDI-PubMed.15980690.s17.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e1" e2="DDI-PubMed.15980690.s17.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e2" e2="DDI-PubMed.15980690.s17.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s17.e2" e2="DDI-PubMed.15980690.s17.e3" /></sentence><sentence text=" The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA"><entity charOffset="81-83" id="DDI-PubMed.15980690.s18.e0" text="EFV" /><entity charOffset="147-149" id="DDI-PubMed.15980690.s18.e1" text="SIM" /><entity charOffset="152-154" id="DDI-PubMed.15980690.s18.e2" text="ATR" /><entity charOffset="161-163" id="DDI-PubMed.15980690.s18.e3" text="PRA" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e0" e2="DDI-PubMed.15980690.s18.e0" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e0" e2="DDI-PubMed.15980690.s18.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e0" e2="DDI-PubMed.15980690.s18.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e0" e2="DDI-PubMed.15980690.s18.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e1" e2="DDI-PubMed.15980690.s18.e1" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e1" e2="DDI-PubMed.15980690.s18.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e1" e2="DDI-PubMed.15980690.s18.e3" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e2" e2="DDI-PubMed.15980690.s18.e2" /><pair ddi="false" e1="DDI-PubMed.15980690.s18.e2" e2="DDI-PubMed.15980690.s18.e3" /></sentence><sentence text="" /></document>